MiMedx Group, Inc., a biopharmaceutical company, develops and markets regenerative biologics utilizing human placental tissue allografts with patent-protected processes for various sectors of healthcare. It processes the human placental tissue utilizing its proprietary PURION Process to produce allografts. The company's proprietary processing methodology employs aseptic processing techniques in addition to terminal sterilization. Its biomaterial platform technologies include AmnioFix and EpiFix that are tissue technologies processed from human amniotic membrane derived from donated placental tissue for homologous applications; OrthoFlo, an amniotic fluid-derived allograft for homologous applications; Physio, a bone grafting material comprising 100% bone tissue with no added carrier; and CollaFix, a technology platform derived from collagen fiber technology designed to mimic the natural composition, structure, and mechanical properties of musculoskeletal tissues to augment their repair. The company also offers EpiCord, an umbilical cord allograft that provides a connective tissue matrix to replace or supplement damaged or inadequate integumental tissue; AmnioCord, an umbilical cord allograft that offers a protective environment for the healing process; and AmnioFill, a cellular tissue matrix allograft that enhances healing. Its products have applications in the areas of wound care, burns, surgery, orthopedics, spine, sports medicine, ophthalmology, and dentistry. The company sells its products through direct sales force, and independent stocking distributors, and third party representatives in the United States, as well as independent distributors internationally. MiMedx Group, Inc. is headquartered in Marietta, Georgia.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:MDXG
CUSIPN/A
Phone770-651-9100
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E Ratio20.43
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$245.01 million
Price / Sales1.80
Cash Flow$0.1686 per share
Price / Cash23.60
Book Value$1.21 per share
Price / Book3.29
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
Employees690
Outstanding Shares111,040,000
Market Cap$476.34 million
MiMedx Group (NASDAQ:MDXG) Frequently Asked Questions
What is MiMedx Group's stock symbol?
MiMedx Group trades on the NASDAQ under the ticker symbol "MDXG."
How will MiMedx Group's stock buyback program work?
MiMedx Group declared that its Board of Directors has initiated a share buyback program on Wednesday, December 13th 2017, which allows the company to buyback $10,000,000.00 in shares, according to EventVestor. This buyback authorization allows the company to buy shares of its stock through open market purchases. Stock buyback programs are often a sign that the company's board believes its stock is undervalued.
How were MiMedx Group's earnings last quarter?
MiMedx Group Inc (NASDAQ:MDXG) posted its quarterly earnings results on Thursday, October, 26th. The medical equipment provider reported $0.08 EPS for the quarter, meeting the Zacks' consensus estimate of $0.08. The medical equipment provider had revenue of $84.60 million for the quarter, compared to analyst estimates of $84.60 million. The business's quarterly revenue was up 31.4% on a year-over-year basis. During the same period in the previous year, the business posted $0.06 earnings per share. View MiMedx Group's Earnings History.
When is MiMedx Group's next earnings date?
What price target have analysts set for MDXG?
4 brokerages have issued 1-year target prices for MiMedx Group's shares. Their predictions range from $9.00 to $21.00. On average, they expect MiMedx Group's share price to reach $16.00 in the next year. This suggests a possible upside of 302.0% from the stock's current price. View Analyst Price Targets for MiMedx Group.
What is the consensus analysts' recommendation for MiMedx Group?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MiMedx Group in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for MiMedx Group.
What are Wall Street analysts saying about MiMedx Group stock?
Here are some recent quotes from research analysts about MiMedx Group stock:
- 1. Needham & Company LLC analysts commented, "This morning (3/15/18), MDXG issued a press release announcing: 1) management expects 1Q18 revenue to exceed the high end of their guidance range and reiterates their 2018 guidance and 2) the U.S. Department of Justice (DOJ) is reviewing the SEC investigation matters. While MDXG’s business appears to be performing well despite the controversy swirling around the company, we believe investors may continue to heavily discount the fundamentals until more is known about the outcome of the Audit Committee’s investigation, the SEC investigation, and the DOJ review." (3/15/2018)
- 2. According to Zacks Investment Research, "MiMedx is an integrated developer, processor and marketer of patent protected regenerative biomaterial products and bioimplants processed from human amniotic membrane. Innovations in Regenerative Biomaterials is the framework behind their mission to give physicians products and tissues to help the body heal itself. Their biomaterial platform technologies include AmnioFix and EpiFix, their tissue technologies processed from human amniotic membrane that is derived from donated placentas. Through their donor program, a mother delivering via full-term Caesarean section birth can elect in advance of delivery to donate the placenta in lieu of having it discarded as medical waste. They process the human amniotic membrane utilizing their proprietary PURION Process, to produce a safe and effective implant. " (12/8/2017)
Are investors shorting MiMedx Group?
MiMedx Group saw a increase in short interest in July. As of July 31st, there was short interest totalling 56,688,697 shares, an increase of 13.1% from the July 13th total of 50,128,118 shares. Based on an average daily volume of 4,596,881 shares, the days-to-cover ratio is presently 12.3 days. Approximately 55.3% of the company's stock are sold short. View MiMedx Group's Current Options Chain.
Who are some of MiMedx Group's key competitors?
Some companies that are related to MiMedx Group include Tandem Diabetes Care (TNDM), Glaukos (GKOS), Mazor Robotics (MZOR), Cardiovascular Systems (CSII), Luminex (LMNX), Cryolife (CRY), Atrion (ATRI), AtriCure (ATRC), Tactile Systems Technology (TCMD), OraSure Technologies (OSUR), Orthofix International (OFIX), Cerus (CERS), SurModics (SRDX), K2M Group (KTWO) and Intersect ENT (XENT).
Who are MiMedx Group's key executives?
MiMedx Group's management team includes the folowing people:
- Mr. Parker H. Petit, Chairman and Chief Exec. Officer (Age 79)
- Mr. William Charles Taylor, Pres, Chief Operating Officer and Director (Age 50)
- Ms. Alexandra O. Haden, Gen. Counsel and Sec. (Age 43)
- Mr. Edward J. Borkowski, Interim Chief Financial Officer (Age 60)
- Dr. Thomas J. Koob, Chief Scientific Officer (Age 69)
Has MiMedx Group been receiving favorable news coverage?
Press coverage about MDXG stock has trended somewhat positive on Wednesday, according to Accern Sentiment Analysis. The research firm ranks the sentiment of press coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. MiMedx Group earned a news and rumor sentiment score of 0.09 on Accern's scale. They also gave news articles about the medical equipment provider an impact score of 47.04 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the next several days. View Recent Headlines for MiMedx Group.
Who are MiMedx Group's major shareholders?
MiMedx Group's stock is owned by a number of of retail and institutional investors. Top institutional investors include BlackRock Inc. (13.16%), Bank of New York Mellon Corp (1.52%), CIBC Private Wealth Group LLC (1.34%), Schwab Charles Investment Management Inc. (0.60%), Thompson Investment Management Inc. (0.53%) and Massachusetts Financial Services Co. MA (0.50%). View Institutional Ownership Trends for MiMedx Group.
Which institutional investors are selling MiMedx Group stock?
MDXG stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Senzar Asset Management LLC, Massachusetts Financial Services Co. MA, GSA Capital Partners LLP, Summit Creek Advisors LLC, New York State Teachers Retirement System, Federated Investors Inc. PA and Bank of New York Mellon Corp. View Insider Buying and Selling for MiMedx Group.
Which institutional investors are buying MiMedx Group stock?
MDXG stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Think Investments LP, Spark Investment Management LLC, Alps Advisors Inc., Taylor Frigon Capital Management LLC, Raymond James Financial Services Advisors Inc., Eqis Capital Management Inc. and Schwab Charles Investment Management Inc.. View Insider Buying and Selling for MiMedx Group.
How do I buy shares of MiMedx Group?
Shares of MDXG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is MiMedx Group's stock price today?
One share of MDXG stock can currently be purchased for approximately $3.98.
How big of a company is MiMedx Group?
MiMedx Group has a market capitalization of $476.34 million and generates $245.01 million in revenue each year. MiMedx Group employs 690 workers across the globe.
How can I contact MiMedx Group?
MiMedx Group's mailing address is 1775 W OAK COMMONS COURT NE, MARIETTA GA, 30062. The medical equipment provider can be reached via phone at 770-651-9100 or via email at [email protected]
MarketBeat Community Rating for MiMedx Group (NASDAQ MDXG)
MarketBeat's community ratings are surveys of what our community members think about MiMedx Group and other stocks. Vote "Outperform" if you believe MDXG will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MDXG will underperform the S&P 500 over the long term. You may vote once every thirty days.
